BioNTech to shed jobs, plants
Digest more
In an effort to reallocate resources to its growing oncology focus in the face of shrinking COVID-19 vaccine sales, German company BioNTech is slashing a large chunk of its manufacturing footprint, | The German vaccine maker plans to wind down operations at a handful of its sites in Germany plus one in Singapore,
BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its founders. Can its ambitious cancer trials turn it from a one-hit wonder into a biotech giant?
FRANKFURT, May 5 (Reuters) - BioNTech said on Tuesday it would close sites affecting up to 1,860 jobs and buy back up to $1 billion worth of its shares, as the COVID‑19 vaccine maker pivots away from pandemic-era manufacturing and prepares for a leadership transition.
BioNTech shares sank yesterday as disappointing Q1 results prompted layoffs. But long-term investors still have ample reasons to load up on BNTX stock today.
The closed sites include some that came with its $1.25 billion takeover of CureVac last year, and BioNTech has said it hopes to complete the wind-down in the first quarter of 2027. It is also considering the "partial or total sale" of the facilities, if buyers can be found.
Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and
BioNTech (NasdaqGS:BNTX) has started five additional pivotal oncology trials in collaboration with Bristol Myers Squibb. The company has expanded its oncology pipeline with new candidates entering later stage development.
BioNTech is planning site closures affecting up to 1,860 jobs and will buy back $1 billion in shares after announcing the departure of its co-founders. Production of its COVID-19 vaccine will be transferred to Pfizer,
The German company that pioneered one of the first mRNA coronavirus vaccines is halting production, handing the reins to partner Pfizer. BioNTech is restructuring to focus on research and illnesses like cancer.
The German biotech is struggling to redefine itself post-Covid, and an oncology push is part of the solution.